You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 29, 2024

LAMISIL Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


Which patents cover Lamisil, and when can generic versions of Lamisil launch?

Lamisil is a drug marketed by Haleon Us Holdings and Novartis and is included in eight NDAs.

The generic ingredient in LAMISIL is terbinafine. There are twenty-seven drug master file entries for this compound. Additional details are available on the terbinafine profile page.

Drug patent expirations by year for LAMISIL
Drug Prices for LAMISIL

See drug prices for LAMISIL

Drug Sales Revenue Trends for LAMISIL

See drug sales revenues for LAMISIL

Recent Clinical Trials for LAMISIL

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Oregon Health and Science UniversityEarly Phase 1
The Malassezia FoundationEarly Phase 1
Pak Emirates Military HospitalPhase 3

See all LAMISIL clinical trials

Pharmacology for LAMISIL

US Patents and Regulatory Information for LAMISIL

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Haleon Us Holdings LAMISIL terbinafine hydrochloride CREAM;TOPICAL 020980-001 Mar 9, 1999 OTC Yes Yes ⤷  Try a Trial ⤷  Try a Trial ⤷  Try a Trial
Novartis LAMISIL terbinafine hydrochloride TABLET;ORAL 020539-001 May 10, 1996 DISCN Yes No ⤷  Try a Trial ⤷  Try a Trial ⤷  Try a Trial
Novartis LAMISIL terbinafine hydrochloride GRANULE;ORAL 022071-001 Sep 28, 2007 DISCN Yes No ⤷  Try a Trial ⤷  Try a Trial ⤷  Try a Trial
Haleon Us Holdings LAMISIL AT terbinafine GEL;TOPICAL 021958-001 Jul 24, 2006 OTC Yes Yes ⤷  Try a Trial ⤷  Try a Trial ⤷  Try a Trial
Novartis LAMISIL terbinafine hydrochloride CREAM;TOPICAL 020192-001 Dec 30, 1992 DISCN No No ⤷  Try a Trial ⤷  Try a Trial ⤷  Try a Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for LAMISIL

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Novartis LAMISIL terbinafine hydrochloride TABLET;ORAL 020539-001 May 10, 1996 ⤷  Try a Trial ⤷  Try a Trial
Haleon Us Holdings LAMISIL terbinafine hydrochloride CREAM;TOPICAL 020980-001 Mar 9, 1999 ⤷  Try a Trial ⤷  Try a Trial
Haleon Us Holdings LAMISIL terbinafine hydrochloride SOLUTION;TOPICAL 020749-001 Oct 17, 1997 ⤷  Try a Trial ⤷  Try a Trial
Novartis LAMISIL terbinafine hydrochloride TABLET;ORAL 020539-001 May 10, 1996 ⤷  Try a Trial ⤷  Try a Trial
Haleon Us Holdings LAMISIL terbinafine GEL;TOPICAL 020846-001 Apr 29, 1998 ⤷  Try a Trial ⤷  Try a Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

International Patents for LAMISIL

See the table below for patents covering LAMISIL around the world.

Country Patent Number Title Estimated Expiration
Portugal 68448 ⤷  Try a Trial
Finland 782446 ⤷  Try a Trial
Czech Republic 285275 Topická farmaceutická kompozice (TOPIC PHARMACEUTICAL COMPOSITION) ⤷  Try a Trial
Slovakia 281616 ⤷  Try a Trial
United Kingdom 9111477 ⤷  Try a Trial
>Country >Patent Number >Title >Estimated Expiration

Supplementary Protection Certificates for LAMISIL

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
0024587 93C0136 Belgium ⤷  Try a Trial PRODUCT NAME: TERBINAFINE (250 MG) SOUS FORME DE CHLORHYDRATE (281,25 MG); NAT. REG.: 616 S 201 F3 19911031; FIRST REG.: GB PL 0101/0304 19901003
0024587 SPC/GB93/096 United Kingdom ⤷  Try a Trial SPC/GB93/096, EXPIRES: 20050805
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.